Articles related to FDA

Sanbexin’s sublingual formulation offers a potential paradigm shift in acute ischemic stroke treatment, enabling flexible administration outside traditional hospital settings.

The FDA’s new mandate requires all mammography facilities to inform women about their breast density, recognizing its significance in cancer risk and detection challenges.

Erzofri offers a new once-monthly injectable option for treating schizophrenia and schizoaffective disorder, potentially improving medication adherence for some patients.

Neffy®, an FDA-approved intranasal epinephrine spray, demonstrates bioequivalence to injectable epinephrine for anaphylaxis treatment in patients weighing ≥30kg, potentially reducing barriers to rapid intervention.

Zunveyl, a prodrug of galantamine, has been formulated to minimize gastrointestinal absorption, potentially addressing common tolerability issues associated with acetylcholinesterase inhibitors in Alzheimer’s treatment.

Afamitresgene autoleucel offers a novel approach to treating metastatic synovial sarcoma, with an overall response rate of 43.2% in clinical trials, providing a much-needed alternative to traditional chemotherapy.